Hims & Hers Health Inc

Hims & Hers Health Inc(HIMS)の株式分析

$27.710

-1.349 (-4.87%)終値時点

Loading chart…
高値
28.905
始値
28.850
出来高加重平均価格
27.97
出来高
9.82M
時価総額
4.30B
安値
27.300
売買代金
274.71M
EV/EBITDA(TTM)
-18.35

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.

www.forhims.com

AI分析 of Hims & Hers Health Inc (HIMS)

中立

Hims & Hers Health Inc is currently a hold. The stock is trading at $28.07, which is below several analyst price targets, including $32 from JPMorgan and $35 from Barclays. However, the company is facing significant challenges, including a net loss of $142 million and a declining gross margin of 63.83%. The recent insider sale of 6,236 shares by the Chief Legal Officer, despite retaining a significant stake, raises concerns about management's confidence amid a 45% decline in stock price over the past year. The main risk is the ongoing class action lawsuit that could impact the company's reputation and financial standing.

バリュエーション指標

Hims & Hers Health Inc(HIMS)の現在の予想PERは73.53で、5年平均は18.47です。

予想PER

適正
5年平均 P/E
18.47
現在のP/E
73.53
割高
76.27
割安
-39.34

予想EV/EBITDA

適正
5年平均 EV/EBITDA
13.59
現在のEV/EBITDA
-18.35
割高
46.29
割安
-19.12

予想PSR

適正
5年平均 P/S
2.48
現在のP/S
1.71
割高
3.53
割安
1.43

Alphio AI による HIMS の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%HIMS

$133.17

シナリオ価格

基

基本

基本 · 50%HIMS

$111.56

シナリオ価格

弱

弱気

弱気 · 25%HIMS

$85.01

シナリオ価格

HIMS を保有するクジラ

B

BIT Capital GmbH

+ を保有HIMS

-3.90%

3か月リターン

C

Casdin Capital, LLC

+ を保有HIMS

-4.80%

3か月リターン

H

HANSAINVEST Hanseatische Investment-GmbH

+ を保有HIMS

-13.69%

3か月リターン

W

Wolverine Asset Management, LLC

+ を保有HIMS

-15.57%

3か月リターン

HIMS のよくある質問 — Alphio AI が回答

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

Hims & Hers Health Inc is currently a hold. The stock is trading at $28.07, which is below several analyst price targets, including $32 from JPMorgan and $35 from Barclays. However, the company is facing significant challenges, including a net loss of $142 million and a declining gross margin of 63.83%. The recent insider sale of 6,236 shares by the Chief Legal Officer, despite retaining a significant stake, raises concerns about management's confidence amid a 45% decline in stock price over the past year. The main risk is the ongoing class action lawsuit that could impact the company's reputation and financial standing.

コミュニティ

もっと見る ↗
jade_estuary2026/10/16

HIMS stock ended a three-day decline on peptide hopes: the Trump administration is reviewing a plan that could open a $2.2B market. $HIMS

もっと見る
登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める